ABOUT BERGENBIO
BGBIO
BerGenBio is a clinical-stage oncology company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers.
https://www.bergenbio.com/category/news/
https://www.nordnet.no/fullscreen/news/1001498364-bergenbio-meets-efficacy-endpoint-for-first-stage-of-phase-ii-trial-with-axl-inhibitor-bemcentinib-in-comb-note-this-headline-has-been-truncated?_ga=2.73223123.1526503989.1578902784-92352681.1557919048
Trinity Delta Analysis:
https://www.trinitydelta.org/companies/bergenbio/
BGBIO
BerGenBio is a clinical-stage oncology company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers.
https://www.bergenbio.com/category/news/
https://www.nordnet.no/fullscreen/news/1001498364-bergenbio-meets-efficacy-endpoint-for-first-stage-of-phase-ii-trial-with-axl-inhibitor-bemcentinib-in-comb-note-this-headline-has-been-truncated?_ga=2.73223123.1526503989.1578902784-92352681.1557919048
Trinity Delta Analysis:
https://www.trinitydelta.org/companies/bergenbio/
Related publications
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Related publications
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.